XSTO
ITECH
Market cap83mUSD
Oct 09, Last price
69.80SEK
1D
1.90%
1Q
2.95%
IPO
191.08%
Name
I-Tech AB
Chart & performance
P/E
25.23
P/S
4.98
EPS
2.77
Div yield, %
2.53%
Shrs. gr., 5y
0.08%
Rev. gr., 5y
26.06%
Revenues
168m
-6.32%
Net income
33m
-14.92%
CFO
65m
+83.67%
Dividend
May 22, 20261.25 SEK/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
I-Tech AB, a biotechnology firm established in Mölndal, Sweden, in 2000, focuses on creating and commercializing products to prevent biofouling. Their flagship innovation is Selektope, a unique bio-repellent ingredient engineered for marine coatings. This compound provides crucial protection against hard fouling on ships, primarily by temporarily stimulating the swimming behavior of barnacle larvae, thereby preventing them from attaching to coated surfaces. The company's primary clientele is the marine coatings industry.
Key people
Philip Chaabane
Chairman of the Board · since 2024
Markus Joehnsson
Chief Executive Officer · since 2025
Magnus Henell
Chief Financial Officer, Director - Operations · since 2024
Per Svensson
Director of Sales and Marketing · since 2021
Markus Hoffman
Director of Research and Development · since 2023
Cecilia Ohlauson
Director Regulatory Affairs and Sustainability · since 2013
Tomas Tedgren
Director · since 2024
Staffan Asplund
Independent Director · since 2025
Tomas Bergdahl
Independent Director · since 2020
Raouf Kattan
Independent Director · since 2022
Chatarina Schneider
Independent Director · since 2020
Headquarters & legal address
Förändringens gata 10
Mölndal, O 431 53
SE
Mölndal, O 431 53
SE
Address
Forandringens gata 10
Molndal, O 431 53
SE
Molndal, O 431 53
SE
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||